101 related articles for article (PubMed ID: 23821002)
1. BAG3 is a novel serum biomarker for pancreatic adenocarcinomas.
Falco A; Rosati A; Festa M; Basile A; De Marco M; d'Avenia M; Pascale M; Dal Piaz F; Tavano F; Di Mola FF; di Sebastiano P; Berloco PB; Nudo F; Caraglia M; Febbraro A; Barcaroli D; Scarpa A; Pezzilli R; De Laurenzi V; Turco MC
Am J Gastroenterol; 2013 Jul; 108(7):1178-80. PubMed ID: 23821002
[No Abstract] [Full Text] [Related]
2. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
3. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
[TBL] [Abstract][Full Text] [Related]
4. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis.
Dhall D; Suriawinata AA; Tang LH; Shia J; Klimstra DS
Hum Pathol; 2010 May; 41(5):643-52. PubMed ID: 20149413
[TBL] [Abstract][Full Text] [Related]
5. Identification of serum biomarker signatures associated with pancreatic cancer.
Wingren C; Sandström A; Segersvärd R; Carlsson A; Andersson R; Löhr M; Borrebaeck CA
Cancer Res; 2012 May; 72(10):2481-90. PubMed ID: 22589272
[TBL] [Abstract][Full Text] [Related]
6. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary and Pancreatic: Pancreatic cancer with elevated serum IgG4 level due to multiple myeloma mimicking localized autoimmune pancreatitis.
Kato S; Kuwatani M; Kawakubo K; Sugiura R; Hirata K; Tanikawa S; Mitsuhashi T; Shiratori S; Sakamoto N
J Gastroenterol Hepatol; 2018 Jul; 33(7):1310. PubMed ID: 29761833
[No Abstract] [Full Text] [Related]
8. Preventing pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis: cost effectiveness of IgG4.
Hughes DB; Grobmyer SR; Brennan MF
Pancreas; 2004 Aug; 29(2):167. PubMed ID: 15257110
[No Abstract] [Full Text] [Related]
9. Evaluation of serum diagnosis of pancreatic cancer by using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Gao H; Zheng Z; Yue Z; Liu F; Zhou L; Zhao X
Int J Mol Med; 2012 Nov; 30(5):1061-8. PubMed ID: 22941199
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
11. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay.
Liberati D; Marzinotto I; Brigatti C; Dugnani E; Pasquale V; Reni M; Balzano G; Falconi M; Piemonti L; Lampasona V
Cancer Biomark; 2018; 22(2):351-357. PubMed ID: 29660901
[TBL] [Abstract][Full Text] [Related]
12. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers in pancreatic cancer diagnosis.
Herreros-Villanueva M; Gironella M; Castells A; Bujanda L
Clin Chim Acta; 2013 Mar; 418():22-9. PubMed ID: 23305796
[TBL] [Abstract][Full Text] [Related]
14. An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas.
Fukamachi K; Tanaka H; Hagiwara Y; Ohara H; Joh T; Iigo M; Alexander DB; Xu J; Long N; Takigahira M; Yanagihara K; Hino O; Saito I; Tsuda H
Biochem Biophys Res Commun; 2009 Dec; 390(3):636-41. PubMed ID: 19818733
[TBL] [Abstract][Full Text] [Related]
15. Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS.
Xue A; Gandy RC; Chung L; Baxter RC; Smith RC
Pancreatology; 2012; 12(2):124-9. PubMed ID: 22487522
[TBL] [Abstract][Full Text] [Related]
16. A and B blood group antigens in human pancreatic ductal adenocarcinomas.
Handra-Luca A
Oncology; 2013; 84(3):141-9. PubMed ID: 23257765
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
18. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
[TBL] [Abstract][Full Text] [Related]
19. Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer.
Basile A; De Marco M; Festa M; Falco A; Iorio V; Guerriero L; Eletto D; Rea D; Arra C; Lamolinara A; Ballerini P; Damiani V; Rosati A; Sala G; Turco MC; Marzullo L; De Laurenzi V
Mol Oncol; 2019 Jun; 13(6):1388-1399. PubMed ID: 30973679
[TBL] [Abstract][Full Text] [Related]
20. Methylation profile of circulating plasma DNA in patients with pancreatic cancer.
Melnikov AA; Scholtens D; Talamonti MS; Bentrem DJ; Levenson VV
J Surg Oncol; 2009 Feb; 99(2):119-22. PubMed ID: 19065635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
